Advertisement

The Clinical Aspects of Inherited Defects in Pyrimidine Degradation

  • M. Tuchman
Conference paper

Abstract

Degradation pathways of pyrimidine bases are common to uracil, thymine, and the halogenated analogues of uracil and involve the same enzymes (Fig. 1). Cytosine nucleotides undergo deamination to form uracil nucleotides before entering the pyrimidine degradation pathway. Degradation of uracil and thymine occurs mainly in the liver although other tissues are also involved in this metabolic process (Levine et al. 1974; Naguib et al. 1985). The first degradative enzyme of this pathway is dihydropyrimidine dehydrogenase (DPD; EC 1.3.1.2.), an NADPH-dependent enzyme that reversibly reduces uracil and thymine forming dihydrouracil (DHU) and dihydrothymine (DHT), respectively. DPD enzymatic activity, which is considered rate limiting, is highest in the liver; however, it can be measured in most other tissues including white blood cells and cultured skin fibroblasts. The next degradative step involves enzymatic cleavage of the dihydropyrimidine ring by dihydropyrimidine amidohydrolase (DHPH; EC 3.5.2.2) followed by degradation of ureidopropionate and ureidoisobutyrate to from (β-alanine and (β-aminoisobutyrate, respectively, by the enzyme uriedopropionase (UP; EC 3.5.1.6). The latter two enzymes are expressed exclusively in liver. The (β-alanine and (β-aminoisobutyrate are then further metabolized to carbon dioxide and ammonia.

Keywords

Pyrimidine Base Culture Skin Fibroblast Pyrimidine Metabolism Orotic Aciduria Dihydropyrimidine Ring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bakkeren JAJM, de Abreu RA, Sengers RCA, Gabreels FJM, Maas JM, Renier WO (1984) Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency. Clin Chim Acta 140: 247–256Google Scholar
  2. Berglund G, Greter J, Lindstedt S, Steen G, Waldenstrom J, Wass U (1979) Urinary excretion of thymine and uracil in a two-year-old child with a malignant tumor of the brain. Clin Chem 25: 1325–1328PubMedGoogle Scholar
  3. Chaudhuri NK, Mukherjee KL, Heidelberger C (1958) Studies on fluorinated pyrimidines. VII — the degradative pathway. Biochem Pharm 1: 328–341Google Scholar
  4. De Abreu RA, Bakkeren JAJM, Braakhekke J, Gabreels FJM, Maas JM, Sengers RCA (1986) Dihydrothymine dehydrogenase deficiency in a family, leading to elevated levels of uracil and thymine. Adv Exp Med Biol 195A: 77–80PubMedGoogle Scholar
  5. Diasio RB, Beavers, TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil- induced toxicity. J Clin Invest 81: 47–51PubMedCrossRefGoogle Scholar
  6. Duran M, Rover P, de Bree PK, Schreuder CH, Beukenhorst H, Dorland L, Berger R (1991) Dihydropyrimidinuria: a new inborn error of pyrimidine metabolism. J Inher Metab Dis 14: 367–370Google Scholar
  7. Levine RL, Hoogenraad NJ, Kretchmer N (1974) A review: Biological and clinical aspects of pyrimidine metabolism, Pediatr Res 8: 724–734Google Scholar
  8. Naguib FNB, el Kouni MH, Cha S (1985) Enyzmes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405–5412PubMedGoogle Scholar
  9. Tuchman M, Stoeckeler JS, Kiang DT, O’Dea RF, Ramnaraine ML, Mirkin BL (1985) Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313: 245–249PubMedCrossRefGoogle Scholar
  10. Tuchman M, O’Dea RF, Ramnaraine MLR, Mirkin BL (1988) Pyrimidine base degradation in cultured murine C-1300 neroblastoma cells and in situ tumours. J Clin Invest 81: 425–430PubMedCrossRefGoogle Scholar
  11. Tuchman M, Roemeling RV, Hrushesky WAM, Sothern RB, O’Dea RF (1989) Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells. Enzyme 42: 15–24PubMedGoogle Scholar
  12. Wadman SK, Beemer FA, de Bree PK, Duran M, van Gennip AH, Ketting D, van Sprang FJ (1984) New defects of pyrimidine metabolism. Adv Ezp med Biol 165A: 109–114Google Scholar
  13. Wadman SK, Berger R, Duran M, de Brce PK, Stoker-de Vries SA, Beemer FA, Weits Binnerts JJ, Penders TJ, van der Woude JK (1985) Dihydropyrimidine dehydrogenase deficiency leading to thymineuraciluria. An inborn error of pyrimidine metabolism. J Inher Metal, Dis 8 (suppl2): 113–114Google Scholar
  14. Wilcken B, Hammond J (1985) Dihydropyrimidine dehydrogenase deficiency - a further case. J Inher Metal, Dis 8 (Suppl 2): 115–116Google Scholar

Copyright information

© Springer Verlag, Berlin Heidelberg 1993

Authors and Affiliations

  • M. Tuchman

There are no affiliations available

Personalised recommendations